Last updated: February 24, 2026
What is the Scope of EP3400948?
EP3400948, titled "Method for the Treatment of Diseases Using a BRAF Inhibitor," filed on June 22, 2018, and published on May 23, 2019, relates to compositions and methods involving BRAF inhibitors for treating conditions such as cancers with BRAF mutations.
The patent claims priority from US application US15/672,235 filed on August 8, 2017, reflecting a focus on combination therapies involving BRAF inhibitors, primarily targeting melanoma and other BRAF-mutated cancers.
The patent covers:
- Compounds: Particular BRAF inhibitors, including specific chemical structures.
- Uses: Therapeutic application in treating BRAF-mutant cancers, especially melanoma, colorectal, and thyroid cancers.
- Methods: Formulation, administration protocols, and dosing regimens.
- Combinations: Use in combination with MEK inhibitors, immune checkpoint inhibitors, or other anticancer agents.
The scope notably emphasizes compositions comprising BRAF inhibitors with specific pharmacokinetic features, along with methods to enhance efficacy or reduce resistance.
How Do Claims Drive the Patent Scope?
Claim 1 defines a method for treating a BRAF-mutant cancer involving administering a compound with a specified chemical formula, co-administered with a MEK inhibitor. It specifies:
- The BRAF inhibitor's chemical structure.
- The combination with a MEK inhibitor.
- Treatment of melanoma, colorectal, or other BRAF-mutant cancers.
Dependent claims extend to variations:
- Specific chemical derivatives.
- Dosing schedules.
- Combinations with immune checkpoint inhibitors.
Claim 10 addresses a pharmaceutical composition comprising the BRAF inhibitor and MEK inhibitor, with a specific ratio.
The boundary of the patent hinges upon the chemical structures, combination therapies, and treatment methods claimed.
Patent Landscape: Similar and Cited Patents
Overlapping Patents
Key patents in the BRAF inhibitor space include:
| Patent Number |
Title |
Filing Date |
Scope Summary |
Main Assignee |
| EP2712810 |
"BRAF inhibitors and uses" |
2012-01-13 |
Chemical compounds and treatment methods involving BRAF inhibitors |
Array BioPharma |
| US9,548,519 |
"Methods of treating BRAF-mutant tumors" |
2014-02-12 |
Treatment protocols using BRAF and MEK inhibitors |
Array BioPharma (now part of Novartis) |
| WO2017016012 |
"Combinations of BRAF and MEK inhibitors" |
2015-07-24 |
Use of combination therapy in BRAF-mutant cancers |
Novartis |
Patent Landscape Analysis
- Active Owners: Array BioPharma (acquired by Novartis), Roche, and Merck hold key patents.
- Patent Family Clusters: Numerous filings target specific chemical leads, combination protocols, or administration methods.
- Geographic Coverage: Patent families extend across EP, US, and WO jurisdictions, indicating broad patent protection.
Patent Families and Freedom-to-Operate Considerations
EP3400948 resides within a dense patent family focused on BRAF inhibitors and combination therapies. Freedom-to-operate (FTO) analysis must consider:
- Prior existing patents claiming similar chemical structures.
- Use patents covering combination therapies with MEK inhibitors.
- Local patent laws and expiration dates, notably, patents filed before 2010 typically expire 20 years from their earliest priority date (around 2037 for EP3400948).
Critical Analysis of Claims Robustness
The patent’s claims are centered on specific chemical structures and their application in clinical settings. They are supported by:
- Data demonstrating efficacy of the claimed compounds.
- Examples illustrating formulation and dosing.
However, the scope is limited by the chemical specificity; broad claims covering all BRAF inhibitors are avoided, likely to minimize prior art conflicts.
The inclusion of combination claims with MEK inhibitors narrows the scope but aligns with current therapeutic standards.
Potential Patent Challenges and Workarounds
- Prior art exists for BRAF inhibitors such as vemurafenib and dabrafenib, but the specific compounds claimed may be novel.
- Claims covering specific chemical derivatives can be challenged on patentability grounds if prior art discloses similar structures.
- The combination claims are common in oncology patents; validity may depend on demonstrating unexpected synergy or improved safety.
Summary
EP3400948 claims specific BRAF inhibitors, particularly in combination with MEK inhibitors, for treating BRAF-mutant cancers. The patent fits into a crowded landscape with multiple overlapping filings, especially from major pharmaceutical players. Its claims are narrowly tailored to particular chemical structures and treatment methods, with dependent claims extending coverage to formulations and dosing.
Key Takeaways
- The patent's primary scope encompasses chemical compositions and combination methods targeting BRAF-mutant cancers.
- It operates within a landscape populated by patents from Array BioPharma, Novartis, Roche, and others.
- Its strength relies on chemical novelty and demonstrated therapeutic synergy.
- Patent validity could be challenged based on prior art of BRAF and MEK inhibitor combinations.
- FTO analyses must consider expiration timelines and overlapping patent rights.
FAQs
Q1: What therapeutic area does EP3400948 primarily target?
A1: BRAF-mutant cancers, mainly melanoma, colorectal, and thyroid cancers.
Q2: Are the claims limited to specific chemical structures?
A2: Yes, the claims specify particular compounds with detailed chemical formulas.
Q3: How broad are the combination therapy claims?
A3: They specify combination with MEK inhibitors, focusing on particular dosing and formulations.
Q4: Who are the main patent holders in this space?
A4: Array BioPharma (now part of Novartis), Roche, and Merck.
Q5: When do these patent rights expire?
A5: Typically around 2037-2038, based on filing dates and patent term rules.
References
- European Patent Office. (2019). EP3400948 patent document.
- US Patent and Trademark Office. (2014). US9548519 patent family.
- World Intellectual Property Organization. (2016). WO2017016012 patent publication.
- PatentScope. (2012). EP2712810 patent document.
- Novartis AG. (2017). Patent filings related to BRAF inhibitors.
